Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Down 80.8% in January

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 174,100 shares, a decline of 80.8% from the January 15th total of 909,000 shares. Based on an average trading volume of 4,260,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.6% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating and set a $7.00 price target on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

Windtree Therapeutics Price Performance

WINT opened at $0.17 on Thursday. Windtree Therapeutics has a 12 month low of $0.10 and a 12 month high of $14.75. The stock has a market capitalization of $1.88 million, a P/E ratio of -0.01 and a beta of 0.53. The business has a 50 day simple moving average of $0.26 and a 200-day simple moving average of $2.61.

Windtree Therapeutics (NASDAQ:WINT) last issued its earnings results on Tuesday, November 26th. The company reported ($4.23) EPS for the quarter, missing the consensus estimate of ($2.27) by ($1.96). Research analysts anticipate that Windtree Therapeutics will post -5.66 EPS for the current year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.